Back to Search
Start Over
The Value and Clinical Significance of
- Source :
- OncoTargets and therapy
- Publication Year :
- 2020
-
Abstract
- Chunhe Zhang,1,* Shaowei Fu,1,* Luyue Wang,1,* Fang Wang,1 Dan Wu,1 Xiangyi Zhe,1 Huizhen Xin,1 Hongtao Li,1 Dongmei Li,1 Fuyuan Jin,1 Renfu Shao,2 Zemin Pan1 1Department of Biochemistry and Molecular Biology, School of Medicine, Shihezi University, Xinjiang Endemic and Ethnic Disease and Education Ministry Key Laboratory, Shihezi, Xinjiang 832002, People’s Republic of China; 2School of Science, Technology and Engineering, Genecology Research Centre, University of the Sunshine Coast, Sippy Downs, Queensland 4556, Australia*These authors contributed equally to this workCorrespondence: Zemin Pan; Xiangyi ZheDepartment of Biochemistry and Molecular Biology, School of Medicine, Shihezi University, Xinjiang Endemic and Ethnic Disease and Education Ministry Key Laboratory, Shihezi, People’s Republic of ChinaEmail panteacher89@sina.com; 342480821@qq.comIntroduction: The aim of this study was to determine whether ZNF582 gene methylation and tissue protein expression can be used as a tool with high sensitivity and specificity for cervical cancer screening. We analyzed the correlation between promoter methylation of ZNF582 gene and cervical cancer and high risk HPV16/18 infection.Methods: Tissue samples of normal cervical or chronic cervicitis (n=51), CIN (cervical intraepithelial neoplasia) (n=35), and cervical carcinoma (n=68) were tested for HPV16/18 infection by polymerase chain reaction (PCR). We also detected the methylation status of the ZNF582 gene promoter in the same tissues by methylation-specific PCR (MSP), then analyzed the correlation between ZNF582 promoter methylation and HPV16/18 infection. Immunohistochemistry was used to analyze ZNF582 gene expression in 152 cervical tissues. We detected ZNF582 mRNA expression in cervical tissues (including cancer and non-cancer) by real-time fluorescence quantitative PCR (qPCR).Results: Among 93 high-grade cervical lesions (CINII and above) and cervical cancer samples, 57 cases were positive for HPV16/18 infection and 36 cases were negative. ZNF582 gene methylation occurred in 9 out of 51 cases in normal cervical tissues (17.6%), 16 of 35 cases in CIN tissues (45.7%), and 50 of 68 cases in cervical cancer (73.5%). The differences in methylation rate of the three groups were statistically significant (P< 0.05). The ZNF582 methylation rate in the positive HPV16/18 infection group was 73.7%, while the negative group was 63.9%. Compared with normal tissues, ZNF582 protein was highly expressed in cervical cancer tissues, but mRNA expression was low.Conclusion: While ZNF582 protein is highly expressed in cervical cancer tissues, it was not sufficient for use as a standard for cervical cancer staging. On the other hand, ZNF582 promoter methylation had high specificity and sensitivity in detecting CINII and highly diseased cervical lesions and could be used as a diagnostic marker for cervical cancer of women.Keywords: cervical cancer, ZNF582 gene, promoter methylation, HPV16/18, gene expression
- Subjects :
- 0301 basic medicine
Pathology
medicine.medical_specialty
cervical cancer
HPV16/18
promoter methylation
Cervical intraepithelial neoplasia
OncoTargets and Therapy
03 medical and health sciences
0302 clinical medicine
medicine
Pharmacology (medical)
Original Research
Cervical cancer
business.industry
Cancer
Methylation
medicine.disease
Cervical cancer staging
030104 developmental biology
Real-time polymerase chain reaction
Oncology
030220 oncology & carcinogenesis
DNA methylation
gene expression
Immunohistochemistry
ZNF582 gene
business
Subjects
Details
- ISSN :
- 11786930
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- OncoTargets and therapy
- Accession number :
- edsair.doi.dedup.....800b6d62d846d7531150ef639538f37f